Multiple myeloma
This product can be combined with melphalan and prednisone (MP regimen) for the treatment of multiple myeloma patients who have not previously been treated and are not suitable for high-dose chemotherapy and bone marrow transplantation; or as a single agent for the treatment of at least one or the treatment of multiple myeloma patients who relapse after more than one treatment.
Mantle cell lymphoma
This product can be used for the treatment of patients with relapsed or refractory mantle cell lymphoma. This patient has received at least one treatment before using this product. The safety and effectiveness data for this indication comes from a foreign single-arm phase II clinical study of mantle cell lymphoma that relapsed after previous treatment. There is still a lack of clinical research data for the Chinese population.
